Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene is attractive because NGN-401 now has a stronger competitive and mechanistic profile in Rett syndrome, with mouse data supporting EXACT-regulated full-length MeCP2 by Day 7 and weakening the case for preferring TSHA-102’s regulation. The clinical signal is also compelling, as 8/10 Phase 1/2 participants met Embolden’s composite endpoint at 12 months, with 10/10 improving on CGI-I and gaining at least one milestone, while gains deepened to 4.7 milestones on average at ≥12 months and 47 total milestones were gained without plateau through up to 30 months. Financially, Neurogene has enough balance-sheet strength to execute, with pro forma cash of about $360.2M and runway into 1Q29 after ~$134.8M net proceeds, supporting PPQ completion by YE26 and the expected 2H27 readout.

Neurogene is facing a materially challenged investment case because the core EXACT premise is undermined by evidence that miRARE and EXACT showed similar transgene expression in both MeCP2-expressing and deficient neurons across cortex, hippocampus, brainstem, and spinal cord, weakening the claim of selective regulation. The clinical and regulatory profile is also unfavorable: there have been cases of HLH/hyperinflammatory syndrome at the current clinical dose of 1E15 vg, response rates in the registrational trial have been described as 35% required versus 80% observed to date, and prior FDA alignment on using the ongoing single-arm, natural history-controlled EMBOLDEN study for BLA support has been reversed. Commercially, intracerebroventricular administration remains a major burden for physicians and caregivers, and in a non-degenerative disease like RTT, families may delay one-time treatment to preserve future next-generation options.